Garle Impex Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 20 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 Cr
as on 18-07-2024
- Satisfied Charges ₹ 5.00 M
as on 18-07-2024
- Revenue -4.99%
(FY 2023)
- Profit -29.64%
(FY 2023)
- Ebitda -11.61%
(FY 2023)
- Net Worth 18.36%
(FY 2023)
- Total Assets -19.14%
(FY 2023)
About Garle Impex
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rukhmani Goyal and Raj Goyal serve as directors at the Company.
- CIN/LLPIN
U52206MP2004PTC016691
- Company No.
016691
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Gwalior, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Garle Impex Private Limited offer?
Garle Impex Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Biochemistry Analyzer, IVDs & Analyzers, Infusion Syringes & Supplies, Syringes, Blood Collection Tubes.
Who are the key members and board of directors at Garle Impex?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rukhmani Goyal  | Director | 11-Jun-2004 | Current |
| Raj Goyal | Director | 11-Jun-2004 | Current |
Financial Performance of Garle Impex.
Garle Impex Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.99% decrease. The company also saw a substantial fall in profitability, with a 29.64% decrease in profit. The company's net worth Soared by an impressive increase of 18.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Garle Impex?
In 2023, Garle Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 23 Jan 2024 | ₹1.20 Cr | Open |
Icici Bank Limited Creation Date: 23 May 2015 | ₹5.00 M | Satisfied |
How Many Employees Work at Garle Impex?
Unlock and access historical data on people associated with Garle Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Garle Impex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Garle Impex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
